SB 9200/tenofovir disoproxil fumarate

Drug Profile

SB 9200/tenofovir disoproxil fumarate

Alternative Names: SB 11399; SB 9200/tenofovir disoproxil fumarate - Spring Bank Pharmaceuticals; Tenofovir disoproxil fumarate/SB 9200

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Spring Bank Pharmaceuticals
  • Class Antiretrovirals; Antivirals; Nucleotides; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action DDX58 protein stimulants; Immunostimulants; NOD2 protein antagonists; Nucleotide reverse transcriptase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Hepatitis B

Most Recent Events

  • 12 Oct 2017 Clinical trials in Hepatitis B in USA (PO) before October 2017 (Spring Bank Pharmaceuticals pipeline, October 2017)
  • 12 Oct 2017 Spring Bank Pharmaceuticals plans a phase III trial for Hepatitis B in USA in 2019 (Spring Bank Pharmaceuticals pipeline, October 2017)
  • 01 Aug 2016 Preclinical trials in Hepatitis B in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top